Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A CONTROLLED TRIAL OF INTRAVENOUS IMMUNE GLOBULIN FOR THE PREVENTION OF SERIOUS INFECTIONS IN ADULTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
Autore:
KIEHL MG; STOLL R; BRODER M; MUELLER C; FOERSTER EC; DOMSCHKE W;
Indirizzi:
UNIV MUNSTER,DEPT INTERNAL MED,ALBERT SCHWEITZER STR 33 D-48129 MUNSTER GERMANY
Titolo Testata:
Archives of internal medicine
fascicolo: 22, volume: 156, anno: 1996,
pagine: 2545 - 2550
SICI:
0003-9926(1996)156:22<2545:ACTOII>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
BACTERIAL-INFECTIONS; DEFICIENCY-SYNDROME; IMMUNOGLOBULIN; CHILDREN; AIDS; PNEUMONIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
M.G. Kiehl et al., "A CONTROLLED TRIAL OF INTRAVENOUS IMMUNE GLOBULIN FOR THE PREVENTION OF SERIOUS INFECTIONS IN ADULTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION", Archives of internal medicine, 156(22), 1996, pp. 2545-2550

Abstract

Background: Studies on human immunodeficiency virus-infected childrensuggest that high-dose immune globulin therapy might be beneficial inreducing the episodes of recurrent infections. In adults, comparable studies are not available. Objective: To determine the efficacy of intravenous (IV) immune globulin therapy in preventing infections and reducing days with fever, as well as the duration and frequency of hospitalization for human immunodeficiency virus-infected adults, in a prospective, randomized outpatient clinical trial. Methods: Adult patients who met Centers for Disease Control and Prevention criteria B and C were randomized to be treated with (n=70) or without (n=57) IV immune globulin. Patients who were assigned to treatment with IV immune globulin received 400 and 200 mg/kg of this drug initially and every 21 days thereafter, respectively. Primary end points were the occurrence of laboratory-proved or clinically diagnosed infections and death caused byinfection. Results: In comparison with patients in the control group,IV immune globulin treatment significantly increased the time for which the patients who met Centers for Disease Control and Prevention criteria B and C were free from serious infection (P<.001). Twelve (17%) of the patients who received IV immune globulin had infection-related deaths compared with 20 (35%) of the control patients; however, this was not statistically significant (P=.06). Furthermore, immune globulintreatment was associated with an overall reduction in the number and duration of hospitalizations for short-term care (P=.002), days with fever (P<.001), and frequency of diarrhea (P<.001). Because of these results, the study was stopped by the local ethical board. Conclusion: Prophylactic IV immune globulin treatment in human immunodeficiency virus-infected adults decreases the frequency of serious infections and is associated with a reduction of hospitalization for shortterm care.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 00:11:37